Bruker Corporation Overview
Industry: Medical Devices
Sector: Healthcare
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts. Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BS Read MoreMavefund brings filings, fundamentals, valuation, price history and news for Bruker Corporation into one research view. The sections below show what strengthens or weakens the research case.
Score
Reported Results
What the company reported, with filing details kept small.
Quarterly result summary
Revenue was $823.4M (+2.7% YoY); EPS was $0.31 (reported).
What changed
- Revenue +2.7% YoY to $823.4M; EPS reported to $0.31.
- Net income -7% YoY to $15.7M.
Guidance / outlook
No formal outlook was extracted from this filing excerpt. Open the SEC source to review full management commentary.
Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.
Other recent earnings materials
Prediction-grade evidence
Recent News
Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.
Bruker Announces Date and Time of Second Quarter 2026 Earnings Release and Webcast
Headline from Yahoo Finance Singapore: Bruker Announces Date and Time of Second Quarter 2026 Earnings Release and Webcast.
Bruker Expands Infection Detection Portfolio with Acquisition of Metagenomic mNGS DISQVER
Headline from Business Wire: Bruker Expands Infection Detection Portfolio with Acquisition of Metagenomic mNGS DISQVER.
Bruker Corp exec Mark Munch sells $120,500 in shares
Headline from Investing.com: Bruker Corp exec Mark Munch sells $120,500 in shares.
Form 4 Bruker Corporation For: 16 July By Investing.com
Headline from Investing.com Canada: Form 4 Bruker Corporation For: 16 July By Investing.com.
Bruker acquires clinical metagenomics platform from Noscendo
Headline from Investing.com UK: Bruker acquires clinical metagenomics platform from Noscendo.
Bruker acquires clinical metagenomics platform from Noscendo
Headline from Investing.com: Bruker acquires clinical metagenomics platform from Noscendo.
Earnings Per Share
Return on Equity
ROE
Company —
Sector Median —
ROE
Company —
Sector Median —
ROE
Company —
Sector Median —
ROE
Company —
Sector Median —
Metric chart temporarily unavailable.
Net Margin
Net Margin
Company —
Sector Median —
Net Margin
Company —
Sector Median —
Net Margin
Company —
Sector Median —
Net Margin
Company —
Sector Median —
Metric chart temporarily unavailable.
Leverage
Leverage
Company —
Sector Median —
Leverage
Company —
Sector Median —
Leverage
Company —
Sector Median —
Leverage
Company —
Sector Median —
Metric chart temporarily unavailable.
Financial Statements
Company-reported SEC EDGAR facts organized into the three core statements.
Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.